Emyria Share Price and Company Fundamentals
Last traded: Last Friday at 6:10 AM
Emyria Limited, a clinical drug development and care delivery company, operates a network of specialist medical clinics. Its product pipeline include EMD-003, a cannabinoid medicine for treating patients with mental health; and EMD-004, a cannabinoid medicine targeting irritable bowel syndrome. The company also provides a data platform that manages, monitors, and improves the safety and efficacy of novel treatments for patients with unmet medical needs. In addition, its medical clinics offer treatments, such as cannabinoid-based medicines. The company has a partnership agreement with Mind Medicine Australia to develop a national care program and data registry for psychedelic-assisted therapies. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was founded in 2018 and is headquartered in Leederville, Australia.
|Primary activities||Operates a network of specialist medical clinics and uses purpose built software and technology to gather clinical data from consenting patients. The anonymised data is commercialised as clinical evidence.|
|Industry / Sector||Health Information Services / Healthcare|
|Mailing address||D2, 661 Newcastle Street Leederville WA 6007 Australia|
|Phone / Fax||1300 436 363 /|
|Share registry||AUTOMIC REGISTRY SERVICES|
Emyria does not pay dividends.
As of Sep 2021, following are the company executives and directors listed on Emyria.
|Dr. Stewart James Washer B.Sc., BSc (Hons), Ph.D.||Exec. Chairman||50||200k|
|Dr. Michael Winlo||MD & Director||376.34k|
|Dr. Alistair Vickery||Exec. Medical Director & Director||371.2k|
|Mr. Simon Robertson C.A., B.Bus, M Appl. Fin, CA||Company Sec.|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Emyria is 59.71M and its enterprise value is 48.59M. The enterprise value to revenue ratio of EMD is 24.59.
Companies similar to Emyria (EMD)
- Ansell (ANN)
- Cochlear (COH)
- Estia Health (EHE)
- Fisher & Paykel Healthcare Corporation (FPH)
- Healius (HLS)
- Nanosonics (NAN)
- Polynovo (PNV)
- Pro Medicus (PME)
- Ramsay Health Care (RHC)
- Resmed Inc (RMD)
- Sonic Healthcare (SHL)
Emyria (ASX:EMD) Frequently Asked Questions
1. What is Emyria's Stock Symbol?
Emyria trades on ASX under the ticker symbol "EMD".
2. What is Emyria's stock price today?
One share of EMD stock can currently be purchased for approximately $0.235.
3. How can I contact Emyria?
Emyria's mailing address is D2, 661 Newcastle Street Leederville WA 6007 Australia. The company can be reached via phone at 1300 436 363.
4. What is Emyria's official website?
The official website of Emyria is http://www.emyria.com.
5. Which share registry manages Emyria's stock?
Emyria's stock is managed by AUTOMIC REGISTRY SERVICES.